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Objectives. This study sought to determine whether coronary
endothelial dysfunction exists in patients with acute-onset idio-
pathic dilated cardiomyopathy (DCM) and to explore its relation
to recovery of left ventricular systolic function in this patient
population.
Background. Coronary endothelial dysfunction exists in
chronic DCM, but its importance in the development and pro-
gression of ventricular dysfunction is not known. To address this
issue we studied coronary endothelial function in patients with
idiopathic DCM <6 months in duration and explored the relation
between coronary endothelial function and subsequent changes in
left ventricular ejection fraction (LVEF).
Methods. Ten patients with acute-onset idiopathic DCM (du-
ration of heart failure symptoms 2.0 6 0.4 months [mean 6
SEM]) and 11 control patients with normal left ventricular
function underwent assessment of coronary endothelial function
during intracoronary administration of the endothelium-dependent
vasodilator acetylcholine and the endothelium-independent vasodi-
lator adenosine. Coronary cross-sectional area (CSA) was deter-
mined by quantitative coronary angiography and coronary blood
flow (CBF) by the product of coronary CSA and CBF velocity
measured by an intracoronary Doppler catheter. Patients with
DCM underwent assessment of left ventricular function before
and several months after the study.
Results. Acetylcholine infusion produced no change in coronary
CSA in control patients but significant epicardial constriction in
patients with DCM (236 6 11%, p < 0.01). These changes were
associated with increases in CBF in control patients (1118 6
49%, p < 0.01) but no change in patients with DCM. Infusion of
adenosine produced increases in coronary caliber and blood flow
in both groups. Follow-up assessment of left ventricular function
was obtained in nine patients with DCM 7.0 6 1.7 months after
initial study, at which time LVEF had improved by >20.10 in four
patients. Multiple linear regression revealed a positive correlation
between both the coronary CSA (r2 5 0.57, p < 0.05) and CBF
(r2 5 0.68, p < 0.01) response to acetylcholine and the subsequent
improvement in LVEF.
Conclusions. Coronary endothelial dysfunction exists at both
the microvascular and the epicardial level in patients with acute-
onset idiopathic DCM. The preservation of coronary endothelial
function in this population is associated with subsequent improve-
ment in left ventricular function.
(J Am Coll Cardiol 1998;32:216–24)
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The etiology of the ventricular dilation and dysfunction that
occur in idiopathic dilated cardiomyopathy (DCM) is un-
known. Although some studies have observed inflammation in
response to a viral or autoimmune insult (1,2) in patients with
DCM, frequently no evidence of infection, autoantibodies or
inflammation can be demonstrated (3,4). Even when active
inflammation can be found, it is often patchy (5) and therefore
does not readily explain the global nature of the myocardial
dysfunction seen in these patients. It has been hypothesized
that diffuse subendocardial ischemia due to altered coronary
physiology may contribute to the global cardiac dysfunction
seen in DCM (6) and that more focal coronary involvement
may account for the regional ventricular wall motion abnor-
malities that are sometimes observed (7).
Abnormal responses to vasodilating stimuli have been
demonstrated in patients (8–11) with, and in animal models
(12,13) of, DCM. Abnormalities in the vasodilator response of
both the coronary (8,10,11) and the systemic (9,14) circulation
have been identified. These studies have documented a failure
to augment blood flow in response to a variety of stimuli known
to cause arterial dilation through endothelium-dependent
mechanisms. The finding that the blunted coronary responses
of patients with DCM to endothelium-dependent vasodilators
occur in the absence of epicardial constriction has been used to
suggest that the vasomotor abnormalities in DCM are re-
stricted to the microvasculature (8).
Previous investigations of coronary vasomotor responses in
patients with DCM have studied patients with chronic DCM
(11) or have not specified the duration of DCM (8–10).
Therefore, it has not been possible to determine whether
coronary vascular abnormalities exist early in the course of
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DCM. Insights into the potential role of these abnormalities in
the pathogenesis and progression of DCM have consequently
been elusive. To determine whether abnormal coronary phys-
iology exists early in the course of DCM, we studied coronary
vascular responses to both the endothelium-dependent vaso-
dilator acetylcholine and the endothelium-independent vaso-
dilator adenosine in patients with acute-onset (within the
preceding 6 months) DCM. We reasoned that if abnormal
coronary physiology does not exist early in the course of DCM,
then it is unlikely to play a role in the pathogenesis and
progression of the myopathic state. In addition, we sought to
define the relation between coronary endothelial function
early in the course of DCM and subsequent changes in left
ventricular function.
Methods
Study patients. The study group included seven men and
three women with acute-onset DCM. Patients were eligible for
the study if they had symptoms of congestive heart failure
(CHF), such as dyspnea, fatigue or edema for #6 months and
were found to have a left ventricular ejection fraction (LVEF)
#0.40. Patients were excluded from study if they had decom-
pensated CHF preventing them from resting supine, a history
of heavy ethanol abuse, severe hypertension, primary valvular
disease or other known cause of DCM. The control group
included six men and five women with undiagnosed chest pain
and normal left ventricular chamber dimensions (left ventric-
ular end-diastolic dimension ,55 mm) and systolic function
(LVEF .0.50). Seven of the 11 control patients underwent
treadmill exercise testing with thallium imaging within 8 weeks
of catheterization. No test showed electrocardiographic evi-
dence of ischemia. Six of seven patients had no defects on
thallium imaging, and the remaining patient had a mild
superior septal reversible defect. All subjects underwent diag-
nostic cardiac catheterization before the study and were found
to have no significant epicardial atherosclerotic disease. The
study protocol was approved by the subcommittee on human
studies at Massachusetts General Hospital. Written informed
consent was obtained from all patients.
Cardiac catheterization. After an overnight fast, patients
received premedication with 5 mg of diazepam and 25 to 50 mg
of diphenhydramine and were brought to the catheterization
laboratory. All vasoactive medications, including alpha- and
beta-adrenergic blocking agents, calcium channel blocking
agents, angiotensin converting-enzyme inhibitors, digoxin and
nitrates were withheld for 12 to 24 h before the procedure.
Internal jugular venous and femoral artery access was
obtained and systemic anticoagulation achieved with 3,000 to
5,000 U of intravenous heparin. Right and left heart catheter-
ization with coronary angiography and, in some cases (six
patients with DCM, eight control patients), left ventriculogra-
phy were performed. Nonionic contrast media (Omnipaque,
Nycomed) was used in all cases. After diagnostic catheteriza-
tion, additional intravenous heparin was given to reach a total
of 10,000 U. An 8F guiding catheter was placed into the ostium
of the left coronary artery. A 3F catheter with a 20-MHz pulsed
Doppler crystal tip (Millar Instruments) was placed over a
0.010-in. high torque floppy guide wire and into the guiding
catheter. The use of this catheter for the measurement of
relative changes in coronary blood flow (CBF) velocity has
been previously described (15,16). The Doppler catheter was
connected to a zero-cross velocimeter (Millar Instruments)
from which flow velocity signals were obtained. Under fluoro-
scopic guidance the guide wire was advanced into the middle
portion of the left anterior descending or, in one control
patient, into the nondominant left circumflex coronary artery.
The Doppler-tipped catheter was then advanced over the wire
into the proximal portion of the artery, and the wire was
removed. The quality of the Doppler signal was checked, and
the image intensifier position was adjusted to provide the
optimal view of the vessel, with priority given to the portion
within 5 mm of the Doppler tip. Thereafter, the imaging
geometry and patient were kept stationary to ensure reproduc-
ibility of the angiographic view. The Doppler range gate was
then adjusted to optimize the flow velocity signal and was
subsequently held constant throughout the protocol. Coronary
angiography was performed through the guiding catheter using
a power injector (Medrad) set to deliver contrast medium at a
constant volume and rate (8 to 9 ml at 5 to 7 ml/s).
Experimental protocol. After a control period, the follow-
ing agents were administered into the coronary artery at
0.8 ml/min through the Doppler catheter for 3 min using an
infusion pump (Baxter Healthcare): 1) a control solution (C1)
of 5% dextrose in water (the acetylcholine vehicle); 2) three
successive doses of acetylcholine, to yield estimated coronary
concentrations of 1028, 1027 and 1026 mol/liter (assuming
coronary artery blood flow of 80 ml/min [17]); 3) a control
solution (C2) of 0.9% NaCl (the adenosine vehicle); and 4)
adenosine to achieve an estimated coronary concentration of
1024 mol/liter, a dose previously shown to produce maximal
coronary vasodilation (18). Heart rate, mean arterial pressure
(MAP) and mean CBF velocity were monitored during all
infusions. After 3 min of each infusion, and before terminating
the infusion, these hemodynamic variables were recorded, and
coronary angiography was performed. Drug infusion was
stopped and the study protocol terminated in the event of the
patient developing prolonged chest pain, electrocardiographic
Abbreviations and Acronyms
CBF 5 coronary blood flow
CHF 5 congestive heart failure
CSA 5 cross-sectional area
DCM 5 dilated cardiomyopathy
LVEF 5 left ventricular ejection fraction
LVSWI 5 left ventricular stroke work index
MAP 5 mean arterial pressure
PCWP 5 pulmonary capillary wedge pressure
C1 5 control solution of 5% dextrose in water
(acetylcholine vehicle)
C2 5 control solution of 0.9% NaCl (adenosine vehicle)
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evidence of ischemia or severe epicardial coronary constric-
tion.
Quantitative coronary angiography. Coronary angiograms
were analyzed using a CMS workstation (Medis, Leiden, The
Netherlands), the use and validation of which have been
described previously (19,20). For each condition, the first
end-diastolic frame in which the study artery was fully opaci-
fied was chosen and digitized in a matrix size of 512 3 512
pixels with 8-bit brightness resolution. Images were calibrated
to the guiding catheter. A minimal cost contour detection
algorithm was used, and edge detection was modified by data
from the modulation transfer function of the system. The mean
coronary artery diameter was measured over a 1-mm length
surrounding the Doppler range. Coronary artery cross-
sectional area (CSA) was then calculated, assuming a cylindri-
cal artery, by the equation CSA 5 (D2)p/4, where D is the
quantitative diameter of the study vessel. CBF was then
calculated as the product of mean CBF velocity and coronary
CSA. Relative changes in CBF and CSA are reported as the
percent change compared with the preceding control infusion.
Hemodynamic measurements. Initial LVEF was deter-
mined by echocardiography (n 5 15 [9 patients with DCM, 6
control patients]) within the 3 weeks before the study for
patients with DCM and within 12 weeks of the study for
control patients or by contrast angiography (n 5 6 [1 patient
with DCM, 5 control patients]) at the time of study. Follow-up
LVEF was determined by echocardiography (n 5 8) or radio-
nuclide ventriculography (n 5 1). Left ventricular stroke work
index (LVSWI) was calculated as (MAP 2 PCWP) 3 SVI 3
0.0136, where PCWP is pulmonary capillary wedge pressure,
and SVI is stroke volume index, calculated as the quotient of
cardiac index and heart rate. The rate–pressure product was
calculated as the product of MAP and heart rate.
Endomyocardial biopsy. After completion of the drug in-
fusion protocol, patients with DCM, at the discretion of the
referring physician, underwent right ventricular (n 5 4), left
ventricular (n 5 1) or biventricular (n 5 5) endomyocardial
biopsy. Right ventricular biopsies were performed through the
right internal jugular or femoral vein using a bioptome (Cor-
dis) advanced through a sheath to the right ventricular apical
septum as guided by orthogonal fluoroscopic views. Left
ventricular biopsies were performed through the femoral ar-
tery using a bioptome advanced through a long sheath to the
left ventricular inferior wall. Four biopsy samples were taken
from each ventricle, with an effort made to vary the sampling
site within the ventricle. Specimens were fixed in buffered 10%
formalin. Paraffin-embedded samples were sectioned and
stained with hematoxylin-eosin, Masson’s trichrome and
Congo red and were examined by light microscopy. Specimens
were categorized according to previously published criteria
(21), and myocyte hypertrophy and fibrosis were graded by
semiquantitative means.
Statistical analysis. Results are expressed as mean value 6
SEM. Clinical and hemodynamic comparisons between groups
were made using the unpaired Student t test or chi-square test,
as appropriate. Comparisons between conditions were made
using two-way analysis of variance, followed by the paired
Student t test corrected for repeated measures (using the
Fisher least significant difference test). These analyses were
performed after the interaction term in the two-way analysis of
variance was found to not be significant (p . 0.10). Changes in
coronary CSA and CBF are reported as significant if both the
actual values of CSA and CBF and the relative changes in
these variables reached significance. Multiple linear regression
was used to examine the relation between clinical and hemo-
dynamic variables (age, duration of CHF symptoms, serum
sodium, initial LVEF, heart rate, MAP, PCWP, LVSWI and
coronary CSA and CBF responses to acetylcholine and aden-
osine) and follow-up LVEF. Significance was considered to be
at the p , 0.05 level.
Results
Clinical characteristics. Table 1 summarizes selected clin-
ical and laboratory characteristics of the patients with acute-
onset DCM. There were no differences in age (47 6 5 [range
Table 1. Clinical Characteristics of Patients With Acute-Onset Dilated Cardiomyopathy
Pt. No./
Gender
Age
(yr)
Duration
of Sx
(mo)
NYHA
Functional
Class LVEF
LVEDD
(mm)
Biopsy
Result
1/F 63 0.75 2 0.25 55 H
2/F 35 2 2 0.30 52 Nl
3/M 51 0.5 2 0.18 99 Fib, H
4/M 18 3 2 0.27 74 Fib, H
5/M 63 5 2 0.40 59 Fib
6/M 30 2 2 0.25 74 Fib, H
7/M 44 1 2 0.12 63 H
8/M 35 0.75 2 0.16 60 H
9/M 71 3 3 0.30 67 Fib, H
10/F 57 2 3 0.22 56 Fib, H
Mean 6 SEM 47 6 5 2.0 6 0.4 2.2 6 0.1 0.25 6 0.03 66 6 4
F 5 female; Fib 5 fibrosis; H 5 myocyte hypertrophy; LVEDD 5 left ventricular end-diastolic diameter; LVEF 5
left ventricular ejection fraction; M 5 male; Nl 5 normal biopsy; NYHA 5 New York Heart Association; Pt 5 patient;
Sx 5 heart failure symptoms.
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18 to 71] vs. 58 6 3 [range 36 to 75] years) or gender
distribution (three women, seven men vs. five women, six men,
p 5 NS for both) between the DCM and control groups. The
mean duration of CHF symptoms in patients with DCM was
2.0 6 0.4 months (range 0.5 to 5). All patients with DCM were
in New York Heart Association class II or III at the time of
study. The groups did not differ in the prevalence of the
following risk factors for atherosclerotic disease: smoking (5
[50%] of 10 patients with DCM vs. 8 [73%] of 11 control
patients); hyperlipidemia (total serum cholesterol $200 mg/dl)
(4 [40%] of 10 patients with DCM vs. 7 [64%] of 11 control
patients); diabetes mellitus (0 [0%] of 10 patients with DCM
vs. 3 [27%] of 11 control patients). There was a greater
prevalence of a history of hypertension in the control group (1
[10%] of 10 patients with DCM vs. 9 [82%] of 11 control
patients, p , 0.05).
Hemodynamic measurements. All patients were in sinus
rhythm at the time of the study, with the exception of three
patients with DCM (Patients 5, 8, 9) who were in atrial
fibrillation with a controlled ventricular response. Baseline
hemodynamic variables for the two groups are shown in Table
2. The DCM group had a lower LVEF, MAP and LVSWI and
a higher heart rate and PCWP than the control group. The
rate-pressure product did not differ between the groups.
During acetylcholine infusion, the rate–pressure product in-
creased by ;10% in both groups: peak rate–pressure product
8,694 6 902 mm Hg/min with 1026 mol/liter acetylcholine in
the DCM group; peak rate–pressure product 8,016 6 458 mm
Hg/min with 1027 mol/liter acetylcholine in the control group
(both p , 0.05 vs. C1). At no dose of acetylcholine or
adenosine did the rate–pressure product differ between
groups, and at each point in the protocol MAP remained lower
and heart rate higher in patients with DCM than in control
patients.
Coronary responses. The drug protocol was completed in
19 of 21 patients (10 patients with DCM, 9 control patients). In
the two control patients who did not complete the protocol, the
highest concentration of acetylcholine was not given because of
apparent severe epicardial constriction during infusion of the
1027 mol/liter acetylcholine dose in one patient and prolonged
chest pain without epicardial constriction or electrocardio-
graphic evidence of ischemia in the remaining patient. Coro-
nary CSA and CBF at baseline did not differ in the two groups
(CSA 6.4 6 1.0 vs. 4.2 6 1.0 mm2, CBF 29.3 6 5.6 vs. 23.3 6
4.4 ml/min; DCM group vs. control group, p 5 NS for both).
Infusion of acetylcholine produced no change in coronary
CSA in the control group but did produce epicardial constric-
tion in patients with DCM (Fig. 1) In the DCM group, CSA did
not change with 1028 mol/liter acetylcholine (26 6 5% vs. C1,
p 5 NS) but decreased progressively with each of the higher
doses (1027 mol/liter acetylcholine: 217 6 8% vs. C1, p ,
0.05; 1026 mol/liter acetylcholine: 236 6 11% vs. C1, p , 0.01;
both p , 0.05, DCM group vs. control group). Overall, 8 (80%)
of the 10 patients with DCM had a decrease in CSA with 1027
mol/liter acetylcholine compared with 4 (36%) of the 11
control patients (p 5 0.08, DCM group vs. control group).
Infusion of acetylcholine produced an increase in CBF in
control patients but no change in patients with DCM (Fig. 2).
CBF increased in the control group with both 1027 and 1026
mol/liter acetylcholine (1027 mol/liter acetylcholine: 153 6
24% vs. C1; 1026 mol/liter acetylcholine: 1118 6 49% vs. C1;
both p , 0.01 vs. C1). In contrast, there was no change in CBF
in the DCM group with any dose of acetylcholine. The percent
change in CBF was higher in control patients than in patients
with DCM with 1026 mol/liter acetylcholine (1118 6 49% vs.
11 6 18%, p , 0.05).
Infusion of 1024 mol/liter adenosine produced a similar
increase in CSA and CBF in both groups (Fig. 3) (CSA: 137 6
10% for DCM group, 120 6 8% for control group, both p ,
0.01 vs. C2; CBF: 1234 6 53% for DCM group, 1247 6 64%
for control groups, both p , 0.01 vs. C2); (DCM vs. control,
p 5 NS for both CSA and CBF changes).
Endomyocardial biopsy. The results of endomyocardial
biopsy are shown in Table 1. No patient was found to have
myocarditis or borderline myocarditis. However, 8 (80%) of 10
patients were found to have myocyte hypertrophy, 6 (60%) of
Table 2. Baseline Hemodynamic Variables
DCM Group
(n 5 10)
Control Group
(n 5 11)
p
Value
LVEF 0.25 6 0.03 0.66 6 0.02 , 0.01
HR (beats/min) 90 6 6 68 6 4 , 0.01
MAP (mm Hg) 86 6 3 106 6 3 , 0.01
RPP (mm Hg/min) 7,783 6 700 7,312 6 517 NS
PCWP (mm Hg) 13 6 2 7 6 1 , 0.01
LVSWI (gzm/m2) 31 6 4 52 6 5 , 0.01
Data presented are mean value 6 SEM. DCM 5 dilated cardiomyopathy;
HR 5 heart rate; LVEF 5 left ventricular ejection fraction; LVSWI 5 left
ventricular stroke index; MAP 5 mean arterial pressure; PCWP 5 pulmonary
capillary wedge pressure; RPP 5 rate–pressure product.
Figure 1. Epicardial CSA response to graded intracoronary doses of
acetylcholine (Ach) and a 5% dextrose control infusion (C1) in
patients with acute-onset DCM and in control patients (CTRL).
Acetylcholine infusion produced no change in CSA in control patients
but a significant epicardial constriction in patients with DCM. *p ,
0.05, †p , 0.01 versus C1. ‡p , 0.05 versus control patients.
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10 had fibrosis, and 5 (50%) of 10 had both. Only 1 (10%) of
the 10 patients had a normal biopsy result. There was no
association between biopsy findings and the coronary re-
sponses to acetylcholine or adenosine.
Clinical outcome and follow-up of left ventricular function.
Follow-up clinical information was obtained for patients with
DCM 16.0 6 2.1 months (range 4 to 24) after catheterization.
Two patients were free of CHF symptoms and were taking no
medication; six had functional class II symptoms with standard
heart failure medication; one had undergone heart transplan-
tation; and one (Patient 7) was lost to follow-up shortly after
the study. Left ventricular function was assessed 7.0 6 1.7
months (range 1 to 16) after catheterization in nine patients
with DCM. The three patients with DCM with atrial fibrillation
at the time of initial study still had atrial fibrillation at the time
of follow-up evaluation of left ventricular function. LVEF at
follow-up had increased to 0.35 6 0.06 (range 0.15 to 0.63; p 5
0.10 vs. initial study). LVEF increased by $0.10 in four
patients (Patients 1, 2, 9 and 10), and to .0.50 in two (Patients
1 and 2). Multiple linear regression analysis revealed that of
the variables examined, only the coronary CSA and CBF
responses to 1026 mol/liter acetylcholine were significantly
associated with improvement in LVEF (coronary CSA: r2 5
0.57, p , 0.05; CBF: r2 5 0.68, p , 0.01) (Table 3, Fig. 4).
Patients were classified into two groups according to whether
their CBF increased or decreased during infusion of 1026
mol/liter acetylcholine: in group 1 (n 5 4), CBF increased by
45 6 16% (range 9% to 86%); in group 2 (n 5 5) CBF
decreased by 45 6 9% (range 20% to 76%). The gender
distribution was different between the groups (group 1 vs.
group 2: three women, one man vs. no women, five men, p 5
0.047). However, there was no difference between groups in
age (56 6 8 vs. 40 6 7 years), duration of CHF symptoms (2 6
1 vs. 2 6 1 months), functional class (2.5 6 0.3 vs. 2.0 6 0.1),
initial LVEF (0.27 6 0.02 vs. 0.25 6 0.04), left ventricular
end-diastolic dimension (58 6 3 vs. 72 6 6 mm), serum sodium
(138 6 1 vs. 138 6 2 mEq/liter); or PCWP (13 6 4 vs. 14 6
3 mm Hg, group 1 vs. group 2, p 5 NS for all). However, LVEF
at follow-up was significantly greater in group 1 (0.48 6 0.06)
than in group 2 (0.24 6 0.05, p , 0.01).
Discussion
The present study of coronary vascular responses in pa-
tients with acute-onset DCM demonstrates both an impaired
coronary microvascular vasodilator response and an epicardial
vasoconstrictor response to the endothelium-dependent vaso-
dilator acetylcholine. The impaired coronary microvascular
vasodilator response is demonstrated by the occurrence of a
blunted CBF response in the absence of a $50% decrease in
epicardial coronary diameter (8). Our study also demonstrates
an association between preservation of coronary endothelial
Figure 2. CBF response to graded intracoronary doses of acetylcho-
line (Ach) and a 5% dextrose control infusion (C1) in patients with
acute-onset DCM and in control patients (CTRL). Acetylcholine
infusion produced an increase in CBF in control patients but no
change in patients with DCM. *p , 0.01 versus C1. †p , 0.05 versus
patients with DCM.
Figure 3. CSA and CBF responses to intracoronary infusion of 1024
mol/liter adenosine and a 0.9% NaCl control infusion (C2) in patients
with acute-onset DCM and control patients (CTRL). Adenosine
infusion produced significant increases in CSA and CBF in both
groups. The magnitude of the responses did not differ between DCM
and control patients.
Table 3. Multiple Linear Regression Analysis of Clinical and
Hemodynamic Variables and Follow-Up Left Ventricular
Ejection Fraction
Variable r2 Coeff F Value p Value
Age (yr) 0.09 0.68 0.44
Duration of Sx (mo) 0.08 0.64 0.45
Serum sodium (mEq/liter) 0.02 0.12 0.74
Initial LVEF 0.02 0.12 0.74
HR (beats/min) 0.07 0.50 0.50
MAP (mm Hg) 0.05 0.36 0.57
PCWP (mm Hg) 0.04 0.27 0.61
LVSWI (gzm/m2) 0.4 4.64 0.07
%DCSA Ach 0.57 9.15 0.02
%DCBF Ach 0.68 14.9 0.006
%DCSA adenosine 0.20 1.72 0.23
%DCBF adenosine 0.20 1.74 0.23
Ach 5 acetylcholine; Coeff 5 coefficient; %DCBF 5 percent change in
coronary blood flow in response to highest concentration of study drug;
%DCSA 5 percent change in coronary cross-sectional area in response to
highest concentration of study drug; other abbreviations as in Tables 1 and 2.
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function and subsequent improvement in LVEF in patients
with acute-onset DCM.
Coronary endothelial dysfunction. Our finding of epicar-
dial constriction during acetylcholine infusion in acute-onset
patients with DCM has not been seen in previous studies of
chronic idiopathic DCM. The magnitude of this constriction
was considerable: .35% mean decrease in coronary CSA in
response to 1026 mol/liter acetylcholine. Paradoxical arterial
vasoconstriction in response to acetylcholine administration
has been previously reported in patients with hypercholester-
olemia (22,23) and atherosclerosis (24), in heavy smokers (25)
and in an animal model of hypertension (26). It has also been
reported (27) in patients with chronic Chagas heart disease,
both in those with preserved left ventricular function and those
with DCM. The explanation for the finding of epicardial
constriction during acetylcholine infusion is uncertain. Acetyl-
choline is known to cause arterial vasodilation by stimulating
the synthesis and release of nitric oxide from normal endothe-
lium. Nitric oxide subsequently diffuses to the vascular smooth
muscle, where it exerts its relaxing effect through a cyclic
guanosine monophosphate–mediated mechanism. Acetylcho-
line can also stimulate muscarinic receptor-mediated release of
endothelium-derived vasoconstrictor substances, which appear
to be cyclooxygenase dependent (28). Finally, acetylcholine has
a direct constrictor effect on vascular smooth muscle (29).
These mechanisms are in equilibrium in the normal vascula-
ture. At lower concentrations of exogenous acetylcholine
(#1026 mol/liter), vasodilating properties predominate,
whereas at higher concentrations (.1026 mol/liter), vasocon-
striction becomes apparent (30). The epicardial vasoconstric-
tion during acetylcholine infusion seen in our study could
therefore be the result of any one or a combination of the
following: the inability of abnormal endothelium to synthesize
or release nitric oxide normally, enhanced direct smooth
muscle constriction or augmented release of or sensitivity to a
constrictor substance. A lack of smooth muscle responsiveness
to endothelium-derived nitric oxide is possible, although our
findings of similar increase in coronary CSA and CBF with
adenosine administration in patients with DCM and control
patients argue against this possibility and are in agreement
with previous reports (8,10) of preserved coronary responses to
endothelium-independent vasodilators in patients with DCM.
Potential role of coronary endothelial dysfunction in patho-
genesis and progression of DCM. Both the etiology and the
importance of coronary endothelial dysfunction in DCM re-
main controversial. One fundamental question is whether
endothelial dysfunction is a product of the cardiomyopathy and
consequent CHF or is instead a manifestation of the initial
insult that produced the DCM and is therefore potentially
important in the pathogenesis and progression of the myo-
pathic state.
Several lines of evidence point to direct endothelial effects
of agents that may cause DCM. Viruses known to be associated
with myocarditis and DCM have been reported to infect
endothelial cells (31), and autoantibodies directed against
endothelium have been found in viral myocarditis (32).
Trypanosoma cruzi, the causative agent of Chagas heart dis-
ease, induces biochemical and synthetic alterations in infected
cultured endothelial cells (33,34). Finally, ethanol, a relatively
common cause of DCM, has been shown to be toxic to vascular
endothelium (35).
A possible role for abnormal coronary vasomotor physiol-
ogy in the pathogenesis and progression of DCM is suggested
by previous experimental work. Factor et al. (36) demonstrated
the presence of coronary microvascular spasm in the Syrian
hamster model of hereditary DCM, and a similar phenomenon
was found in a murine model of acute Chagas heart disease
(37). Treatment in the hamster model with a calcium channel
antagonist prevented both the spasm and the subsequent
development of DCM (38). To this previous evidence of direct
endothelial involvement with infectious and toxic agents asso-
ciated with DCM, and the potential for abnormal vascular
physiology to produce myocardial dysfunction, we now add the
observation of altered coronary endothelial function in pa-
tients with acute-onset DCM.
Previous studies have documented the presence of abnor-
mal coronary endothelial function in patients with idiopathic
DCM. The patients in the present study differ from those of
previous studies in that the duration of symptoms in our study
was specifically limited. To our knowledge there have been no
previous studies of coronary physiology early in the course of
human DCM. Neglia et al. (7), using positron emission tomog-
raphy, found abnormalities in rest and stress myocardial blood
flow in patients with mild DCM. However, the duration of
Figure 4. Plots of the relation between
coronary responses to acetylcholine infu-
sion and a 5% dextrose control infusion
(C1) and subsequent improvement in
LVEF in patients with acute-onset dilated
cardiomyopathy. Left, Association between
the epicardial CSA response during infu-
sion of 1026 mol/liter acetylcholine and
improvement in LVEF on follow-up.
Right, Association between the CBF re-
sponse during infusion of 1026 mol/liter
acetylcholine and improvement in LVEF at
follow-up.
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cardiac dysfunction in their study was not specified, and they
may have included patients with chronic mild ventricular
dysfunction rather than patients early in the course of DCM.
We also attempted to confine our study cohort to patients
without an obvious cause of DCM. To this end we excluded
patients with DCM and a history of significant hypertension
because previous work has shown coronary (39) and systemic
(40) vascular endothelial abnormalities to be present in hyper-
tension. We also excluded patients with a history of heavy
ethanol abuse because previous studies have suggested that
ethanol-induced DCM may exhibit different coronary endothe-
lial responses than other types of DCM: Treasure et al. (8)
noted an unusually preserved CBF response during acetylcho-
line administration in one of their study patients who had a
history of heavy ethanol abuse (8), and more recent experi-
mental work indicates that although short-term ethanol expo-
sure inhibits endothelium-dependent vasodilation (41), long-
term exposure enhances it by increasing the nitric oxide
synthase response to a variety of stimuli (42).
Relation of coronary endothelial function to recovery of left
ventricular function. In addition to the finding of abnormal
coronary endothelial function in patients with acute-onset
DCM, our current study demonstrates a relation between
preservation of coronary endothelial function and subsequent
improvement in LVEF in these patients. Several previous
studies have reported on the incidence of and predictors for
recovery of LVEF in patients with DCM. The incidence of
improvement has ranged from 27% to 37% (43,44). Predictors
of recovery of LVEF remain controversial. Although some
studies have found a shorter duration of symptoms and a less
severe clinical status at presentation to predict recovery (44),
others have not (43) but have found histopathologic features of
endomyocardial biopsy specimens to be more useful (45). To
our knowledge, the current study is the first to examine the
relation between coronary endothelial function and subse-
quent recovery of LVEF in patients with DCM. We found that
preservation of coronary endothelial function at both the
epicardial (as measured by changes in CSA during acetylcho-
line infusion) and the microcirculatory (as measured by
changes in CBF during acetylcholine infusion) level was asso-
ciated with improvement in LVEF. Furthermore, LVEF im-
proved $0.10 in all patients whose CBF increased with acetyl-
choline infusion but did not improve significantly in patients
whose CBF failed to increase. We were unable to demonstrate
an association between any of the other clinical or hemody-
namic variables, including the presence or absence of fibrosis
or hypertrophy on endomyocardial biopsy and improvement in
LVEF. This relation between preservation of coronary endo-
thelial function and subsequent improvement in LVEF sug-
gests the hypothesis that an abnormal coronary endothelium
plays a role in the establishment and progression of ventricular
dysfunction in DCM.
Clinical implications. If the coronary endothelial abnor-
malities found in patients with acute-onset DCM are important
in the pathogenesis and progression of DCM, they may
represent a target for therapeutic intervention. The previously
cited work by Factor et al. (38) suggests that in some cases,
treatment with a coronary vasodilator may prevent the devel-
opment of DCM. It is conceivable that the efficacy of various
vasodilators in patients with DCM is due in part to their effects
on the coronary circulation. Evidence for this exists for
angiotensin-converting enzyme inhibitors (46), hydralazine
(47) and calcium channel antagonists (48). However, given
their beneficial systemic hemodynamic and, in some cases,
neurohumoral actions, it will be difficult to conclusively estab-
lish a direct benefit of their coronary vasodilator effects.
Study limitations. Contrary to our hypothesis that coro-
nary endothelial dysfunction can play an etiologic and contrib-
utory role in DCM is the possibility that the endothelial
dysfunction is merely a product of the DCM, regardless of the
cause. This contention is supported by a number of observa-
tions: Endothelial dysfunction has been found both in the
peripheral (9,14) and the coronary (8,10,11) circulation and in
patients with various types of DCM, including familial (8),
postpartum (7), ischemic (9) and idiopathic DCM (8,10,11), as
well as in a variety of animal models of DCM (12,13). Among
these is a coronary artery ligation model of CHF in the rat (49),
in which the endothelial abnormalities were not present early
after coronary ligation but only after 4 weeks, when CHF was
fully established.
There are several potential limitations to our present study.
Despite our attempts to study a cohort early in the course of
DCM, it is impossible to know whether the period of time
between the onset of the disease process and the onset of
symptoms was uniform in the study group. Although we may
have included patients with more chronic ventricular dysfunc-
tion than their histories would suggest, it would be difficult to
recruit only patients with DCM in whom the exact duration of
DCM is known. Although vasoactive medications were with-
held for 12 to 24 h before study, the longer acting of these
agents may have residual effects on coronary endothelial
function testing. Our control group, with its relatively high
prevalence of atherosclerotic risk factors, including hyperten-
sion, clearly does not represent a truly “normal” cohort. We
thought it appropriate to enroll as control patients only those
for whom catheterization was clinically indicated. Further-
more, we would have expected the differences between groups
to be even greater had the control group included truly normal
subjects because the presence of these risk factors has in itself
been associated with abnormal endothelial function (22,23).
The methods of assessing LVEF were not completely uniform.
However, most patients (seven of nine) underwent echocardi-
ography at both initial evaluation and follow-up, and analysis
of the results from the three techniques used to assess LVEF
at our institution has shown good agreement. Finally, our
patient cohort was small, and the association found between
coronary endothelial function and improvement in LVEF will
need to be confirmed in a prospective fashion in a larger series.
Conclusions. We have demonstrated the presence of ab-
normal coronary endothelium-dependent vasodilation early in
the course of human DCM. We further showed that this
abnormality exists at both the epicardial and the microcircu-
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latory level. Finally, we demonstrated an association between
preservation of coronary endothelial function and subsequent
improvement in LVEF. The potential diagnostic and therapeu-
tic importance of these findings in acute-onset DCM remains
to be determined.
References
1. Kopecky SI, Gersh BJ. Dilated cardiomyopathy and myocarditis: natural
history, etiology, clinical manifestations and management. Curr Prob Cardiol
1987;12:569–647.
2. Sole MJ, Liu P. Viral myocarditis: a paradigm for understanding the
pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol
1993;22 Suppl A:99A–105A.
3. Latif N, Baker CS, Dunn MJ, Rose ML, Brady P, Yacoub MH. Frequency
and specificity of antiheart antibodies in patients with dilated cardiomyop-
athy detected using SDS-PAGE and Western blotting. J Am Coll Cardiol
1993;22:1378–84.
4. Keeling PJ, Lukaszyk A, Poloniecki J, et al. A prospective case-control study
of antibodies to Coxsackie B virus in idiopathic dilated cardiomyopathy.
J Am Coll Cardiol 1994;23:593–8.
5. Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyo-
cardial biopsy specimens from 38 patients with lymphocytic myocarditis:
implications for role of sampling error. Mayo Clin Proc 1989;64:1235–45.
6. Unverferth DV, Magorien RD, Lewis RP, Leier CV. The role of subendo-
cardial ischemia in perpetuating myocardial failure in patients with nonisch-
emic congestive cardiomyopathy. Am Heart J 1983;105:176–9.
7. Neglia D, Parodi O, Gallopin M, et al. Myocardial blood flow response to
pacing tachycardia and to dipyridamole infusion in patients with dilated
cardiomyopathy without overt heart failure. Circulation 1995;92:796–804.
8. Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of
the coronary microvasculature is impaired in dilated cardiomyopathy. Cir-
culation 1990;81:772–9.
9. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-
dependent vasodilation is attenuated in patients with heart failure. Circula-
tion 1991;84:1589–96.
10. Inoue T, Sakai Y, Morooka S, et al. Vasodilatory capacity of coronary
resistance vessels in dilated cardiomyopathy. Am Heart J 1994;127:376–81.
11. Holdright DR, Clarke D, Fox K, Poole-Wilson PA, Collins P. The effects of
intracoronary substance P and acetylcholine on coronary blood flow in
patients with idiopathic dilated cardiomyopathy. Eur Heart J 1994;15:1537–
44.
12. Mayhan WG, Rubinstein I. Acetylcholine induces vasoconstriction in the
microcirculation of cardiomyopathic hamsters: reversal by L-arginine. Bio-
chem Biophys Res Commun 1992;184:1372–7.
13. Kiuchi K, Sato N, Shannon RP, Vatner DE, Morgan K, Vatner SF.
Depressed beta-adrenergic receptor- and endothelium-mediated vasodila-
tion in conscious dogs with heart failure. Circ Res 1993;73:1013–23.
14. Katz SD, Biasucci L, Sabba C, et al. Impaired endothelium-mediated
vasodilation in the peripheral vasculature of patients with congestive heart
failure. J Am Coll Cardiol 1992;19:918–25.
15. Wilson RF, Laughlin DE, Ackell PH, et al. Transluminal, subselective
measurement of coronary artery blood flow velocity and vasodilator reserve
in man. Circulation 1985;72:82–92.
16. Sibley DH, Millar HD, Hartley CJ, Whitlow PL. Subselective measurement
of coronary blood flow velocity using a steerable Doppler catheter. J Am Coll
Cardiol 1986;8:1332–40.
17. Ganz W, Tamura K, Marcus HS, Donoso R, Yoshida S, Swan HJC.
Measurements of coronary sinus blood flow by continuous thermodilution in
man. Circulation 1971;44:181–95.
18. Cox DA, Vita JA, Treasure CB, et al. Atherosclerosis impairs flow-mediated
dilation of coronary arteries in humans. Circulation 1989;80:458–65.
19. Haase J, Di MC, Slager CJ, et al. In-vivo validation of on-line and off-line
geometric coronary measurements using insertion of stenosis phantoms in
porcine coronary arteries. Cathet Cardiovasc Diagn 1992;27:16–27.
20. Reiber JH, Serruys PW, Kooijman CJ, et al. Assessment of short-, medium-,
and long-term variations in arterial dimensions from computer-assisted
quantitation of coronary cineangiograms. Circulation 1985;71:280–8.
21. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis: a histopatho-
logic definition and classification. Am J Cardiovasc Pathol 1986;1:3–14.
22. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to
acetylcholine relates to risk factors for coronary artery disease. Circulation
1990;81:491–7.
23. Reddy KG, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective
endothelial dysfunction may occur in the absence of angiographic or
ultrasound atherosclerosis in patients with risk factors for atherosclerosis.
J Am Coll Cardiol 1994;23:833–43.
24. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction
induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med
1986;315:1046–51.
25. Nitenberg A, Antony I, Foult JM. Acetylcholine-induced coronary vasocon-
striction in young heavy smokers with normal coronary arteriographic
findings. Am J Med 1993;95:71–7.
26. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to ace-
tylcholine in the aorta of the spontaneously hypertensive rat. Hypertension
1986;8:344–8.
27. Torres FW, Acquatella H, Condado JA, Dinsmore R, Palacios IF. Coronary
vascular reactivity is abnormal in patients with Chagas’ heart disease. Am
Heart J 1995;129:995–1001.
28. Luscher TF, Boulanger CM, Dohi Y, Yang Z. Endothelium-derived con-
tracting factors. Hypertension 1992;19:117–30.
29. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the
relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373–6.
30. Arbustini E, Grasso M, Diegoli M, et al. Morphologic changes induced by
acetylcholine infusion in normal and atherosclerotic coronary arteries. Am J
Cardiol 1993;71:1382–90.
31. Friedman HM, Macarak EJ, MacGregor RR, Wolfe J, Kefalides NA. Virus
infection of endothelial cells. J Infect Dis 1981;143:266–73.
32. Hengstenberg C, Rose ML, Olsen EGJ, Maisch B. Immune response to the
endothelium in myocarditis, dilated cardiomyopathy, and rejection after
heart transplantation. Eur Heart J 1991;12 Suppl D:144–6.
33. Morris SA, Bilezikian JP, Hatcher V, Weiss LM. Trypanosoma cruzi:
infection of cultured human endothelial cells alters inositol phosphate
synthesis. Exp Parasitol 1989;69:330–9.
34. Morris SA, Wittner N, Weiss L, et al. Extracellular matrix derived from
Trypanosoma cruzi infected endothelial cells directs phenotypic expression.
J Cell Physiol 1990;145:340–6.
35. Tarnawski A, Stachura J, Gergely H, Hollander D. Microvascular endothe-
lium—a major target for alcohol injury of the human gastric mucosa. J Clin
Gastroenterol 1988;10 Suppl 1:S53–64.
36. Factor SM, Minase T, Cho S, Dominitz R, Sonnenblick EH. Microvascular
spasm in the cardiomyopathic Syrian hamster: a preventable cause of focal
myocardial necrosis. Circulation 1982;66:342–54.
37. Factor SM, Cho S, Wittner M, Tanowitz HB. Abnormalities of the coronary
microcirculation in acute murine Chagas’ disease. Am J Trop Med Hyg
1985;34:246–53.
38. Factor SM, Cho S, Scheuer J, Sonnenblick EH, Malhotra A. Prevention of
hereditary cardiomyopathy in the Syrian hamster with chronic verapamil
therapy. J Am Coll Cardiol 1988;12:1599–604.
39. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular
hypertrophy are associated with impaired endothelium-mediated relaxation
in human coronary resistance vessels. Circulation 1993;87:86–93.
40. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-
dependent vascular relaxation in patients with essential hypertension. N Engl
J Med 1990;323:22–7.
41. Hatake K, Wakabayashi I, Kakishita E, et al. Inhibitory effect of ethanol on
endothelium-dependent vascular responsiveness. Eur J Pharmacol 1989;168:
277–83.
42. Davda RK, Chandler LJ, Crews FT, Guzman NJ. Ethanol enhances the
endothelial nitric oxide synthase response to agonists. Hypertension 1993;
21:939–43.
43. Dec GW, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of
acute dilated cardiomyopathies. N Engl J Med 1985;312:885–90.
44. Steimle AE, Stevenson LW, Fonarow GC, Hamilton MA, Moriguchi JD.
Prediction of improvement in recent onset dilated cardiomyopathy after
referral for heart transplantation. J Am Coll Cardiol 1994;23:553–9.
45. Figulla HR, Rahlf G, Nieger M, Luig H, Kreuzer H. Spontaneous hemody-
namic improvement or stabilization and associated biopsy findings in pa-
tients with congestive cardiomyopathy. Circulation 1985;71:1095–104.
46. Foult J-M, Tavolaro O, Antony I, Nitenberg A. Direct myocardial and
coronary effects of enalaprilat in patients with dilated cardiomyopathy:
223JACC Vol. 32, No. 1 MATHIER ET AL.
July 1998:216–24 CORONARY ENDOTHELIAL DYSFUNCTION IN ACUTE DCM
assessment by a bilateral intracoronary infusion technique. Circulation
1988;77:337–44.
47. Magorien RD, Brown GP, Unverferth DV, et al. Effects of hydralazine on
coronary blood flow and myocardial energetics in congestive heart failure.
Circulation 1982;65:528–33.
48. Kiowski W, Erne P, Pfisterer M, Mueller J, Buehler FR, Burkart F. Arterial
vasodilator, systemic and coronary hemodynamic effects of nisoldipine in
congestive heart failure secondary to ischemic or dilated cardiomyopathy.
Am J Cardiol 1987;59:1118–25.
49. Teerlink JR, Clozel M, Fischli W, Clozel J-P. Temporal evolution of
endothelial dysfunction in a rat model of chronic heart failure. J Am Coll
Cardiol 1993;22:615–20.
224 MATHIER ET AL. JACC Vol. 32, No. 1
CORONARY ENDOTHELIAL DYSFUNCTION IN ACUTE DCM July 1998:216–24
